“A prospective clinical utility study demonstrates that physicians use the 40-gene expression profile (40-GEP) to guide clinical management decisions for Medicare-eligible patients with cutaneous squamous cell carcinoma (cSCC)”, J of Skin, vol. 6, no. 6, p. s95, Nov. 2022, doi: 10.25251/skin.6.supp.95.